| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Pulmonary arterial hypertension is the life-threatening disease characterized by excessive vascular resistance, smooth muscle cell proliferation in small pulmonary artery, leading to elevation of pulmonary vascular resistance, right ventricular failure and death. Early diagnosis is important because delayed treatment leads to poor prognosis. In this study, we demonstrated that end-tidal carbon dioxide during cardiopulmonary exercise testing strongly correlate with mean pulmonary arterial pressure, leading to the possibility of usefulness of early diagnosis noninvasively. Moreover, soluble RAGE (Receptor for Advanced Glycation End-product) can also be a potential biomarker of early diagnosis, clinical stage, and response of treatment.
|
